Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips On the surface, it may seem as if now’s not the time to buy industrial stocks. With macro issues still unresolved, and the threat of a 2023 global recession still looming, there is a lot of uncertainty surrounding the ne...
Summary Danaher's earnings have had three great years on the back of COVID-related demand. That demand should wane over the next two years. This will likely place pressure on the stock price. Investors who would like to avoid this sort of downside would be wise to take profits. ...
Summary Danaher is now down over 4% since announcing its latest earnings. The life science company reported weak revenue growth and suggests strong headwinds in FY23 from COVID related products. The current valuation is very elevated and represents a significant premium compared to ...
Danaher ( NYSE: DHR ), which reported slowing topline growth in its Q4 2022 financial results earlier Tuesday, is impacting other life sciences tools and services providers. The biggest decliner among peers is Repligen ( NASDAQ: RGEN ), off ~4.3% . Others include Thermo Fi...
Danaher Corporation (DHR) Q4 2022 Results Conference Call January 24, 2023 08:00 AM ET Company Participants John Bedford - Vice President-Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial ...
Summary S&P 500 blended EPS growth for Q4 fell in the most recent week, to -4.6%, the lowest rate in over 2 years. Earnings pick up this week, with MSFT, TSLA, IBM and INTC in focus. Potential wins this week include: Danaher, Weyerhaeuser. Peak weeks for Q4 season are from J...
Despite reporting better than expected Q4 2022 financials, COVID-19 test maker Danaher Corporation ( NYSE: DHR ) indicated a slowdown in topline growth Tuesday as the pandemic impact waned. The Washington, DC-based life sciences company posted ~$8.4B in revenue for the quarter wit...
Danaher press release ( NYSE: DHR ): Q4 Non-GAAP EPS of $2.87 beats by $0.32 . Revenue of $8.37B (+2.8% Y/Y) beats by $430M . For the first quarter 2023, the Company anticipates that non-GAAP base business core revenue growth will be up mid-single digits. For the f...
Danaher Reports Fourth Quarter and Full Year 2022 Results PR Newswire WASHINGTON , Jan. 24, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2022. All results in this release r...
Danaher ( NYSE: DHR ) is scheduled to announce Q4 earnings results on Tuesday, January 24th, before market open. The consensus EPS Estimate is $2.51 (-6.7% Y/Y) and the consensus Revenue Estimate is $7.9B (-2.9% Y/Y). Over the last 2 years, DHR has beaten EPS estimates 100...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...